(ESPR) Esperion Therapeutics, Inc. Business Model Canvas Research

Esperion Therapeutics, Inc. relies on specialty distribution partners to move branded lipid therapies through specialty pharmacies and wholesale networks, which is key for prescription access and refill continuity. For branded drugs, this channel is a core commercial step that helps place product into healthcare systems and keep therapy on hand for patients.

• Drives pharmacy and system access
• Keeps refill flow moving
• Supports commercial availability

Esperion Therapeutics depends on clinical sites, payers, and market access advisors because its LDL-C drugs sell in a guideline-driven cardiovascular market. These partners help generate evidence for reimbursement decisions, which matters in a category where U.S. statin-intolerant or inadequately controlled patients still number in the millions.

• Clinical sites: evidence generation
• Payers: reimbursement access
• Advisors: formulary support

Esperion Therapeutics, Inc. uses medical education to teach prescribers how to manage LDL-C and use its therapies in cardiology and primary care, which matters in a prescription market where adoption depends on physician confidence. In CLEAR Outcomes, bempedoic acid cut major adverse cardiovascular events by 13% and lowered LDL-C by about 20%, giving reps and educators hard data to support uptake.

• Trains cardiology and primary care prescribers
• Explains LDL-C management and product use
• Supports adoption with outcomes data

Esperion Therapeutics, Inc. has to keep its prescription brands available across retail, specialty, and payer channels, so supply chain coordination is a core activity. That means tight forecasting, inventory planning, and manufacturing oversight to avoid stock gaps that can hurt refill rates and physician trust.

• Forecast demand by channel
• Balance inventory with supply
• Monitor manufacturing output closely

Esperion Therapeutics, Inc. relies on patent and exclusivity rights to protect NEXLETOL and NEXLIZET, support pricing power, and slow generic entry. This IP moat is central to keeping its U.S. franchise valuable while the company works to extend coverage into the 2030s.

• Defends against generic competition
• Supports premium pricing
• Protects U.S. franchise value

Esperion Therapeutics, Inc. runs its corporate office from Ann Arbor, Michigan, at 3891 Research Park Drive, Suite 200. The headquarters anchors management and operating control, and it coordinates commercial, regulatory, and development work across the business.

• Ann Arbor, Michigan
• 3891 Research Park Drive
• Centers control functions

Bempedoic acid gives Esperion Therapeutics, Inc. a nonstatin LDL-lowering option for patients who cannot take statins or need add-on therapy. In CLEAR Outcomes, it cut major adverse cardiovascular events by 13% in 13,970 statin-intolerant patients, which gives prescribers a clear alternative beyond statins.

• Nonstatin LDL-C lowering
• Fits statin-intolerant patients
• Broader choice for prescribers

NEXLIZET gives Esperion Therapeutics, Inc. a fixed-dose 180 mg bempedoic acid/10 mg ezetimibe tablet, so patients can intensify LDL-C therapy in one pill instead of two. That simpler dosing supports adherence and lowers pill burden, which matters in high-risk patients who need long-term lipid control.

• 180 mg bempedoic acid + 10 mg ezetimibe
• One tablet, once daily
• Less pill burden than separate therapies

Patient support services are key for Esperion Therapeutics, Inc. because chronic cardiovascular therapy often fails at the pharmacy counter: about 50% of patients with long-term medicines do not take them as prescribed. By using affordability help, onboarding, and refill support, Esperion can cut abandonment and keep more patients on therapy.

• Lower out-of-pocket friction
• Reduce prescription abandonment
• Support daily adherence

Esperion Therapeutics, Inc. relies on medical affairs to keep healthcare professional trust high, with scientific teams answering clinical questions and sharing evidence for its 2 branded therapies. In a data-heavy category like lipid management, that dialogue helps support use decisions and reinforces credibility.

• Scientific evidence builds trust
• Clinical questions get answered fast
• 2 therapies need strong data

Payer formularies decide whether Esperion Therapeutics, Inc. therapies are covered, preferred, or pushed behind prior auth and step edits, so they directly shape prescription demand. Preferred tiering lowers patient out-of-pocket costs and is a key driver of commercial scale.

• Coverage drives access
• Tiering drives demand
• Prior auth slows uptake

Daiichi Sankyo Europe acts as Esperion Therapeutics, Inc.’s partner-led channel outside the U.S., helping move bempedoic acid brands into local markets without Esperion building full sales teams in every country. Licensing can speed access and cut fixed costs, while Esperion keeps more focus on the U.S. and other high-priority markets.

• Partner-led ex-U.S. access
• Lower local build-out costs
• Faster regional launch path

Cardiologists are key prescribers for LDL lowering, especially in ASCVD patients who often need LDL-C below 70 mg/dL. Because they manage complex lipid cases and shape therapy choice, their adoption can drive Esperion Therapeutics, Inc. brand growth.

• High-risk LDL care
• Complex lipid cases
• Adoption drives growth

Primary care physicians see the biggest share of lipid patients, and they start most long-term statin and non-statin therapy. In the U.S., about 86 million adults have high LDL-C, so Esperion needs broad PCP reach to drive screening, initiation, and repeat prescribing.

• Largest ongoing cholesterol prescriber base
• Key for first-line therapy starts
• Supports repeat use and adherence

Esperion Therapeutics, Inc.'s general and administrative cost covers executive, legal, finance, and information systems. In a headquarters-led pharma model, these functions are needed to keep governance tight and day-to-day operations moving.

• Executive oversight
• Legal and finance control
• IT and systems support
• Governance and operations

Esperion Therapeutics, Inc. runs a partnership-heavy model, so licensing and collaboration costs can include milestone payments, royalties, and regional deal fees. This structure shifts part of innovation spending to external partners, but it also means future economics can be shared across licensed products and geographies.

• Milestone payments can rise with progress.
• Royalties apply to licensed sales.
• Regional deals add collaboration costs.

Upfront license payments can give Esperion Therapeutics, Inc. immediate non-dilutive cash when it signs partnering deals for rights to its assets. This matters most for development-stage programs, where a single deal can fund trials and reduce pressure to raise equity.

• Immediate cash from licensing
• Supports non-dilutive funding
• Useful for development-stage assets

Milestone and collaboration income can lift Esperion Therapeutics, Inc. revenue when partners hit R&D, launch, or sales targets, but the cash is uneven because it depends on contract terms and partner progress. In 2025, this line item remained a support stream rather than the core driver, with Esperion's business still led by product sales.

• Depends on partner milestones
• Can fund operating cash needs
• Revenue timing stays irregular